Michael S. Ewer
About
Michael S. Ewer is a scholar working on Oncology, Cardiology and Cardiovascular Medicine and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Michael S. Ewer has authored 62 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 28 papers in Cardiology and Cardiovascular Medicine and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael S. Ewer's work include Cancer Treatment and Pharmacology (31 papers), HER2/EGFR in Cancer Research (31 papers) and Chemotherapy-induced cardiotoxicity and mitigation (26 papers). Michael S. Ewer is often cited by papers focused on Cancer Treatment and Pharmacology (31 papers), HER2/EGFR in Cancer Research (31 papers) and Chemotherapy-induced cardiotoxicity and mitigation (26 papers). Michael S. Ewer collaborates with scholars based in United States, United Kingdom and Switzerland. Michael S. Ewer's co-authors include Robert S. Benjamin, Aman U. Buzdar, Gabriel N. Hortobágyi, Kelly K. Hunt, Steven M. Ewer, Julie Byrne, María Koehler, A. Preston, Erica Rappold and Edith A. Perez and has published in prestigious journals such as JAMA, Circulation and Journal of Clinical Oncology.
In The Last Decade
Michael S. Ewer
61 papers receiving 4.4k citations
Hit Papers
Peers
Michael S. Ewer
Edward H. Romond United States
Aron Goldhirsch Italy
Franco Nolè Italy
Kerry L. Reynolds United States
Peter Barrett‐Lee United Kingdom
N. Colombo Italy
Christopher Poole United Kingdom
B. Ojeda Spain
Chiara Carlomagno Italy
Erica L. Mayer United States
Citations per year, relative to Michael S. Ewer Michael S. Ewer (= 1×)
peers
Edward H. Romond
Countries citing papers authored by Michael S. Ewer
Since
Specialization
Citations
This map shows the geographic impact of Michael S. Ewer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael S. Ewer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael S. Ewer more than expected).
Fields of papers citing papers by Michael S. Ewer
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Michael S. Ewer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael S. Ewer. The network helps show where Michael S. Ewer may publish in the future.
Co-authorship network of co-authors of Michael S. Ewer
This figure shows the co-authorship network connecting the top 25 collaborators of Michael S. Ewer. A scholar is included among the top collaborators of Michael S. Ewer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael S. Ewer. Michael S. Ewer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Dang, Chau T., Michael S. Ewer, Suzette Delaloge, et al.. (2022). BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. Cancers. 14(11). 2596–2596.
2.
Dang, Chau T., Michael S. Ewer, Suzette Delaloge, et al.. (2021). 43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial. Annals of Oncology. 32. S38–S39.
3.
Azambuja, Evandro de, Daniel Eiger, Marion Procter, et al.. (2021). Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab (P+T) in the APHINITY trial.. Journal of Clinical Oncology. 39(15_suppl). 510–510.
4.
Eiger, Daniel, Noam Pondé, Dominique Agbor‐Tarh, et al.. (2020). Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. British Journal of Cancer. 122(10). 1453–1460.
5.
Eiger, Daniel, Noam Pondé, Dominique Agbor‐Tarh, et al.. (2019). Long-term cardiac outcomes of HER2+ breast cancer patients treated in the ALTTO trial. Annals of Oncology. 30. iii65–iii65.
6.
Ewer, Michael S. & Jay Herson. (2018). False Positive Cardiotoxicity Events in Cancer-Related Clinical Trials: Risks Related to Imperfect Noninvasive Parameters. Chemotherapy. 63(6). 324–329.
7.
Cheson, Bruce D., Susan O’Brien, Michael S. Ewer, et al.. (2018). Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas. Clinical Lymphoma Myeloma & Leukemia. 19(3). 135–141.
8.
Ewer, Michael S., et al.. (2015). Cardiac safety of afatinib: a review of data from clinical trials. Cardio-Oncology. 1(1). 3–3.
9.
Buzdar, Aman U., Vera J. Suman, Funda Meric‐Bernstam, et al.. (2013). Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. The Lancet Oncology. 14(13). 1317–1325.
10.
Swain, Sandra M., Michael S. Ewer, Javier Cortés, et al.. (2013). Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double-Blind, Placebo-Controlled Phase III Study. The Oncologist. 18(3). 257–264.
11.
Lorenzo, Giuseppe Di, Riccardo Autorino, Giacomo Cartenì, et al.. (2009). Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Annals of Oncology. 20(9). 1535–1542.
12.
Perez, Edith A., María Koehler, Julie Byrne, et al.. (2008). Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials. Mayo Clinic Proceedings. 83(6). 679–686.
13.
Buzdar, Aman U., Vicente Valero, Nuhad K. Ibrahim, et al.. (2007). Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen. Clinical Cancer Research. 13(1). 228–233.
14.
Ewer, Michael S. & Joyce O’Shaughnessy. (2007). Cardiac Toxicity of Trastuzumab-Related Regimens in HER2-Overexpressing Breast Cancer. Clinical Breast Cancer. 7(8). 22–29.
15.
Tan-Chiu, Elizabeth, Greg Yothers, Edward H. Romond, et al.. (2005). Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31. Journal of Clinical Oncology. 23(31). 7811–7819.
16.
Buzdar, Aman U., Nuhad K. Ibrahim, Daniel J. Booser, et al.. (2005). Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer. Journal of Clinical Oncology. 23(16). 3676–3685.
17.
Ewer, Michael S., Harry R. Gibbs, Joseph Swafford, & Robert S. Benjamin. (1999). Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?. PubMed. 26(4 Suppl 12). 96–101.
18.
Kish, Susannah K., et al.. (1998). Outcome of cardiopulmonary resuscitation in cancer patients admitted to an intensive care unit in a tertiary cancer center. CHEST Journal. 114.
19.
Ewer, Michael S., et al.. (1995). Advance directives in the intensive care unit of a tertiary cancer center. Cancer. 76(7). 1268–1274.
20.
Wallerstein, Ralph O., Gary Spitzer, Frank Dunphy, et al.. (1990). A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer.. Journal of Clinical Oncology. 8(11). 1782–1788.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Edward H. Romond Breakdown of academic impact, for papers by Aron Goldhirsch Breakdown of academic impact, for papers by Franco Nolè Breakdown of academic impact, for papers by Kerry L. Reynolds Breakdown of academic impact, for papers by Peter Barrett‐Lee Breakdown of academic impact, for papers by N. Colombo Breakdown of academic impact, for papers by Christopher Poole Breakdown of academic impact, for papers by B. Ojeda Breakdown of academic impact, for papers by Chiara Carlomagno Breakdown of academic impact, for papers by Erica L. Mayer